V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

RxSight Executive Compensation (FY25)

RXST · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Ron Kurtz
Latest say-on-pay support
=
June 16, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on RxSight

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 16, 2026
5 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
RxSight brief$1,500Get the executive brief
Velarion Member, one year
215 figures on this page: 212 cited to the filing that reported them, 3 calculated from figures it prints. See the citations

More on RxSight

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ron Kurtz: $6,982,453 → $4,650,661 (33.4% lower)
Say-on-pay support: 86.7% → 88.4% (1.7 points higher)
CEO pay ratio: 47:1 → 28:1 (40.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is RxSight's chief executive and what were they paid?
Ron Kurtz, Chief Executive Officer, President and Director, received $4,650,661 in total compensation for fiscal 2025. Kurtz's total was 33.4% lower than the $6,982,453 reported for fiscal 2024.
What was RxSight's say-on-pay result?
Shareholders supported the say-on-pay proposal with 88.4% of votes cast including abstentions in favor at the meeting held June 16, 2026 for fiscal 2025.
Which companies are in RxSight's peer group?
The disclosed peer group includes ADMA Biologics, Inc., Alphatec Holdings, Inc., Artivion, Inc., AtriCure, Inc. and Axonics, Inc., among others.
What is RxSight's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 28:1, against median employee compensation of $164,848.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ron Kurtz
Chief Executive Officer, President and Director
◇———◇—◇◇
Ilya Goldshleger
Chief Operating Officer
◇———◇—◇◇
Shelley Thunen
Former Chief Financial Officer
Departed during or after this year
◇———◇—◇◇
Eric Weinberg
Chief Business Development Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ron Kurtz
Chief Executive Officer, President and Director
◇——◇◇—◇◇
Shelley Thunen
Former Chief Financial Officer
◇——◇◇—◇◇
Ilya Goldshleger
Chief Operating Officer
◇——◇◇—◇◇
Eric Weinberg
Chief Business Development Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ron Kurtz
Chief Executive Officer, President and Director
◇——◇◇—◇◇
Ilya Goldshleger
Chief Operating Officer
◇——◇◇—◇◇
Shelley Thunen
Former Chief Financial Officer
◇——◇◇—◇◇
Eric Weinberg
Chief Business Development Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ron Kurtz
Chief Executive Officer, President and Director
◇——◇◇—◇◇
Eric Weinberg
Chief Business Development Officer
◇——◇◇—◇◇
Shelley Thunen
Former Chief Financial Officer
Departed during or after this year
◇——◇◇—◇◇
Ilya Goldshleger
Chief Operating Officer
◇——◇◇—◇◇
Scott Gaines
Chief Customer Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eric WeinbergOPTION◇——◇—◇◇
Ilya GoldshlegerOPTION◇——◇—◇◇
Ron KurtzOPTION◇——◇—◇◇
Scott GainesRSU◇——◇——◇
Scott GainesRSU◇——◇——◇
Scott GainesOPTION◇——◇—◇◇
Scott GainesOPTION◇——◇—◇◇
Shelley ThunenOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ron KurtzOption◇—◇3/3/2034
Option◇—◇2/26/2035
Option◇—◇3/8/2033
Scott GainesRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/8/2033
Option◇—◇2/26/2035
Option◇—◇7/30/2035
Option◇—◇3/10/2032
Option◇—◇3/3/2034
Option◇—◇8/6/2034
Ilya GoldshlegerOption◇—◇3/3/2034
Option◇—◇8/6/2034
Option◇—◇3/8/2033
Option◇—◇2/26/2035
Shelley ThunenOption◇—◇3/8/2033
Option◇—◇8/6/2034
Option◇—◇2/26/2035
Option◇—◇3/3/2034
Eric WeinbergOption◇—◇3/8/2033
Option◇—◇3/3/2034
Option◇—◇8/6/2034
Option◇—◇2/26/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Raymond W. Cohen
◇◇————◇
J. Andy Corley
Board chair
◇◇————◇
Julie B. Andrews
◇◇————◇
Robert Warner
◇◇————◇
Robert J. Palmisano
◇◇————◇
Juliet Tammenoms Bakker
◇◇————◇
Tamara R. Fountain, M.D
◇◇————◇
Shweta Singh Maniar
◇◇————◇
William J. Link, Ph.D
◇◇————◇
Ron Kurtz, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Board meeting fee◇
Committee meeting fee◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ADMA Biologics, Inc. ADMA
  • Alphatec Holdings, Inc. ATEC
  • Artivion, Inc. AORT
  • AtriCure, Inc. ATRC
  • Axonics, Inc. AXNX
  • Glaukos Corporation GKOS
  • Inari Medical, Inc. NARI
  • Inspire Medical Systems, Inc. INSP
  • iRhythm Technologies, Inc. IRTC
  • LeMaitre Vascular, Inc. LMAT
  • OrthoPediatrics Corp. KIDS
  • PROCEPT BioRobotics Corporation PRCT
  • SI-BONE, Inc. SIBN
  • Silk Road Medical, Inc. SILK
  • STAAR Surgical Company STAA
  • TransMedics Group, Inc. TMDX
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT
  • Vericel Corporation VCEL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 16, 2026=◇◇◇
2024June 3, 2025=◇◇◇
2023June 6, 2024=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Ron Kurtz (Chief Executive Officer, President and Director), FY2025 total compensation $4,650,661 (base salary $630,625) [exec_comp, SEC accession 0001193125-26-187240, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when RxSight files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact RxSight disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where RxSight sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether RxSight's disclosed peer group is defensible, who names RxSight back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
215 figures on this page: 212 cited to the filing that reported them, 3 calculated from figures it prints.
212 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001193125-26-272688
  2. 0001193125-26-187240
    CEO PAY RATIO DISCLOSURE · Director Compensation · Grants of Plan-Based Awards in 2025 · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0000950170-25-081636
  4. 0000950170-24-069895
  5. 0000950170-23-013694
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “RxSight executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RXST (accessed 2026).
Short form: data: Velarion

The paid brief for RxSight

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about RxSight and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers RxSight discloses

The companies named in RXST's own disclosed peer group.

ADMA Biologics, Inc.Alphatec Holdings, Inc.Artivion, Inc.AtriCure, Inc.Glaukos CorporationInari Medical, Inc.Inspire Medical Systems, Inc.iRhythm Technologies, Inc.LeMaitre Vascular, Inc.OrthoPediatrics Corp.PROCEPT BioRobotics CorporationSI-BONE, Inc.Silk Road Medical, Inc.STAAR Surgical CompanyTransMedics Group, Inc.Twist Bioscience CorporationVeracyte, Inc.Vericel Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy